-
Patient recruitment: Recombinant humanized anti-PD-1 monoclonal antibody (HX008) combined
Time of Update: 2021-01-01
Basic information registration number CTR20202387 test status in the applicant contact Wang Liyan first public information date 2020-11-26 applicant name Taizhou Han Zhong Biopharmaceutical Co., Ltd.
-
More than $1 billion! Lilly is licensed exclusively by Xinda BioPD-1 Mono-Anti-China.
Time of Update: 2020-10-15
In addition, two new adaptive applications for the first-line treatment of non-squamous non-small cell lung cancer (NSCLC) and the joint treatment of first-line squamous NSCLC patients by Xindili monoantigen and Gissitalbin have also been accepted by the State Drug Administration (NMPA).
-
Analysis of the indications layout of PD-1/L1 mono-resistant.
Time of Update: 2020-07-29
Introduction: A text understands the differencebetween between China and the United States that have been approved for indications Lung cancer is a preferred indication of both Chinese and American b
-
BMS's PD-1 mono-antiOpdivo, FDA approved for late esophageal squamous cell carcinoma
Time of Update: 2020-06-16
Bristol Myers Squibb inc announced that the FDA has approved its PD-1 monoanti-Opivo (nivolumab) for patients with progressive, recurrent or metastatic esophagus squamous cell carcinoma (ESCC) who we
-
China's State Drug Administration Accepts PD-1 Telli-Zhu-Dan-Ri-Dan-Ri-Dan-Ri-Mono-Resistance Application
Time of Update: 2020-06-11
late last month, Burlinger Ingeheim partner Baiji Shenzhou (NMPA) of China's National Medicines Administration (NMPA) has accepted its PD-1 Tilreju-Ju-Ri-Ju-Ri-Ri-Dan-Ri-Ri-Ri-Dana-ri applicatio
-
State Drug Administration conditionally approves first domestic PD-1 single anti-"Trepri mono-anti-injection" market
Time of Update: 2020-06-10
today, the State Medicines (http:// Regulatory Authority has conditions to approve the first domestic PD-1 mono-resistance - Trepri mono-anti-injection (commodity name: Tuyi) listed this is chin
-
Terrei Pearl mono-resistant wins 2nd indication, the first PD-1 drug approved for UC
Time of Update: 2020-05-30
On April 10, the State Drug Administration (NMPA) updated the status of the PD-1 single anti-Tilelli pearl single anti-injection (commodity name: Baczean ®) (acceptance number: CXSS1900025) to become
-
ASCO 2020: PD-1 mono-anti-Opdivo, CTLA-4 mono-Yervoy combination chemotherapy first-line treatment
Time of Update: 2020-05-29
Bristol Myers Squibb announced the detailed results of its CheckMate-9LA trial, which showed that the use of PD-1 mono-anti-Opdivo (nivolumab) and CTLA-1 mono-resistant Yervoy (ipilimumab) chemothe
-
FDA approves Persimmon Squibb's PD-1 mono-anti-Opdivo and CTLA-4 mono-anti-Yervoy combination, first-line treatment of non-small cell lung cancer
Time of Update: 2020-05-29
Bristol Myers Squibb announced that the FDA has approved a combination of its PD-1 mono-antiOpdivo (nivolumab) and CTLA-4 monoantigen Yervoy (ipilimumab) to treat patients with metastatic non-smal
-
China's urinary skin cancer (UC) the first PD-(L)1 treatment! Baiji Shenzhou Baize an ® (for Reli
Time of Update: 2020-04-11
The ® has been approved by the State Drug Administration (NMPA) for the treatment of patients with recurrent or incurable classic Hodgkin's lymphoma with at least second-line system chemotherapy, as well as platinum-containing chemotherapy failures for the treatment of PD-L1 high expression, including localized advanced or metastatic urinary tract cancer patients within 12 months of advances in new or assisted chemotherapy.
-
T-cell lymphoma new drug! Cinda BioPD-1 inhibitor Dabershu ® (Sindili mono-resistance) was granted the U.S. FDA's certification of orphan drugs!
Time of Update: 2020-03-30
March 30, 2020 / Biovalley BIOON/ -- Innovent Biologic is a biopharmaceutical company dedicated to the development, production and sale of innovative drugs for the treatment of major diseases such